1,060,000 Shares of Xeris Biopharma Holdings, Inc. $XERS Bought by Vilga Financial Planning LLC

Vilga Financial Planning LLC bought a new stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 1,060,000 shares of the company’s stock, valued at approximately $10,134,000. Xeris Biopharma comprises 6.1% of Vilga Financial Planning LLC’s portfolio, making the stock its 3rd biggest position.

Several other institutional investors and hedge funds have also bought and sold shares of XERS. KBC Group NV bought a new position in Xeris Biopharma in the first quarter valued at approximately $27,000. Allworth Financial LP bought a new stake in shares of Xeris Biopharma during the 2nd quarter worth approximately $34,000. State of Wyoming acquired a new stake in shares of Xeris Biopharma in the 2nd quarter valued at approximately $52,000. Integrated Wealth Concepts LLC acquired a new stake in shares of Xeris Biopharma in the 2nd quarter valued at approximately $74,000. Finally, Kingsview Wealth Management LLC bought a new position in shares of Xeris Biopharma in the second quarter valued at $79,000. Institutional investors own 42.75% of the company’s stock.

Xeris Biopharma Price Performance

Shares of Xeris Biopharma stock opened at $10.19 on Friday. The company has a quick ratio of 1.02, a current ratio of 1.45 and a debt-to-equity ratio of 17.00. The stock has a market capitalization of $1.86 billion, a price-to-earnings ratio of -92.64 and a beta of 0.53. Xeris Biopharma Holdings, Inc. has a twelve month low of $5.25 and a twelve month high of $11.33. The company has a 50-day simple moving average of $8.61 and a two-hundred day simple moving average of $7.45.

Xeris Biopharma (NASDAQ:XERS) last announced its earnings results on Thursday, August 6th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of $0.01 by ($0.19). The business had revenue of $92.10 million for the quarter, compared to the consensus estimate of $90.12 million. Xeris Biopharma had a positive return on equity of 338.21% and a negative net margin of 5.12%. Analysts forecast that Xeris Biopharma Holdings, Inc. will post 0.07 EPS for the current year.

Insider Buying and Selling

In other news, insider Kevin McCulloch sold 15,000 shares of the stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $9.41, for a total value of $141,150.00. Following the completion of the transaction, the insider owned 1,599,208 shares of the company’s stock, valued at approximately $15,048,547.28. This represents a 0.93% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Beth Hecht sold 16,666 shares of the firm’s stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $9.41, for a total transaction of $156,827.06. Following the completion of the sale, the insider owned 1,111,130 shares in the company, valued at $10,455,733.30. This represents a 1.48% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 134,998 shares of company stock worth $1,202,666 in the last ninety days. 4.35% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

XERS has been the topic of a number of recent analyst reports. Barclays boosted their target price on shares of Xeris Biopharma from $12.00 to $14.00 and gave the stock an “overweight” rating in a report on Tuesday. Leerink Partners lifted their price objective on shares of Xeris Biopharma from $12.00 to $16.00 and gave the company an “outperform” rating in a research report on Thursday, September 10th. Wall Street Zen upgraded shares of Xeris Biopharma from a “hold” rating to a “buy” rating in a research note on Saturday, September 19th. Finally, Weiss Ratings cut shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $13.20.

Xeris Biopharma Profile

Xeris Biopharma, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology, and related rare or chronic conditions. The company uses proprietary formulation technologies designed to deliver medicines that are difficult to formulate or administer through conventional methods, including its XeriSol and XeriJect platforms.

Xeris’ commercial portfolio includes Gvoke, a ready-to-use glucagon injection used to treat severe hypoglycemia; Keveyis (dichlorphenamide), a treatment for primary periodic paralysis; and Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with Cushing’s syndrome.